Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 194

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 194
---
,632

        $
        4,186

        $
        3,910

        Research and development

        17,081

        20,465

        17,689

        Sales and marketing

        12,370

        14,553

        13,597

        General and administrative

        20,527

        23,704

        20,281

        Total share-based compensation expense
         
        $
        53,610

        $
        62,908

        $
        55,477

114

Adaptive Biotechnologies CorporationNotes to Consolidated Financial Statements (Continued) 

As of December 31, 2024, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows: 

        Unrecognized Share-BasedCompensation Expense(in thousands)

        Remaining Weighted-AverageRecognition Period(in years)

        Nonvested stock options
         
        $
        12,943

        1.51

        Nonvested restricted stock units

        50,803

        2.23

        Nonvested market-based restricted stock units

        8,611

        1.66

15.RestructuringsIn 2022, we implemented a restructuring plan to reduce operating costs and reduced our workforce by approximately 100 employees. We incurred aggregate restructuring costs of $2.0 million, all of which was recognized during the year ended December 31, 2022. These costs primarily related to one-time termination benefits and ongoing benefit arrangements, both of which included severance payments and extended benefits coverage support and were contingent upon the impacted employees’ execution and non-revocation of separation agreements. Our aggregate restructuring costs also included certain contract termination costs. The activities related to this reduction in workforce were primarily completed in March 2022 and the $2.0 million aggregate restructuring costs were paid as of December 31, 2022.During the three months ended March 31, 2024, we implemented a restructuring plan to better align our organization to our two operating segments: MRD and Immune Medicine. We incurred aggregate restructuring costs of $1.0 million, primarily related to one-time termination benefits and ongoing benefit arrangements.During the three months ended June 30, 2024, we implemented additional restructuring initiatives which impacted certain planned software enhancements and resulted in the consolidation of certain research and development workflows. The impacted software enhancements were primarily associated with our